After five years of waiting, Pfizer and Lilly are ready to restart late-stage clinical trials for the pain drug tanezumab, the big pharmas announced 23 March. The move forward scores Pfizer a $200m milestone payment and signals a jumpstart for the class of drugs.
Pfizer/Lilly ready to ditch painful past with new tanezumab trials
After five years of waiting, Pfizer and Lilly are ready to restart late-stage clinical trials for the pain drug tanezumab, the big pharmas announced 23 March. The move forward scores Pfizer a $200m milestone payment and signals a jumpstart for the class of drugs.
More from Alimentary/Metabolic
More from Therapy Areas
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.